News headlines about Summit Therapeutics PLC (NASDAQ:SMMT) have trended somewhat positive on Tuesday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Summit Therapeutics PLC earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.9501570029489 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several equities analysts have recently issued reports on the stock. ValuEngine upgraded shares of Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. Canaccord Genuity reiterated a “buy” rating and set a $28.00 target price on shares of Summit Therapeutics PLC in a report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $24.00 price objective on shares of Summit Therapeutics PLC and gave the stock a “buy” rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research upgraded shares of Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, July 4th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.00.

Shares of Summit Therapeutics PLC (NASDAQ SMMT) traded up 0.21% during trading on Tuesday, reaching $14.50. 2,139 shares of the company were exchanged. Summit Therapeutics PLC has a 1-year low of $5.31 and a 1-year high of $19.75. The firm’s market capitalization is $179.52 million. The company’s 50-day moving average is $11.98 and its 200 day moving average is $11.71.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/08/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-summit-therapeutics-plc-nasdaqsmmt-stock-price.html.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Insider Buying and Selling by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.